Jonathan W. Riess

University of California Davis Medical Center

Also affiliated with UC Davis Comprehensive Cancer Center, University of California, Davis

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

4.3Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 53 papers — median percentile 42. Top paper: “Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer”.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

Nature Communications(2024)10.1038/s41467-024-47423-0

N/A

1.7DataRank · unranked

93 citations

Yu‐Ting Chou, Lauren Čech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas +30 more

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Journal of Clinical Oncology(2024)10.1200/jco.24.00071

N/A

1.4DataRank · unranked

60 citations

Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, Stephen Shiboski +19 more

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2023.4025

N/A

1.1DataRank · unranked

48 citations

Zhonglin Hao, Liza C. Villaruz, Jun Zhang, Jimmy Ruiz, W. Jeffrey Petty +33 more

A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

Cancer Discovery(2013)10.1158/2159-8290.cd-13-0183

N/A

0.885DataRank · unranked

364 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3947

N/A

0.862DataRank · unranked

21 citations

Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner +10 more

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.05.001

N/A

0.789DataRank · unranked

18 citations

Karen L. Reckamp, Paul Frankel, Jeff Longmate, Karen A. Kelly, David R. Gandara +7 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.01.1628

N/A

0.731DataRank · unranked

130 citations

Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda +11 more

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004440

N/A

0.729DataRank · unranked

128 citations

Venkata Nagineni, Arvind Ravi, Ila Datar, Mari Mino–Kenudson, Germán Corredor +11 more

Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

JCO Precision Oncology(2021)10.1200/po.20.00419

N/A

0.510DataRank · unranked

29 citations

Christie J. Lau, Marina S.D. Milan, Julianna Supplee, Jonathan W. Riess, Penelope A. Bradbury +4 more

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.11.020

N/A

0.494DataRank · unranked

26 citations

Robyn Du, Nathaniel J. Myall, Whitney E. Lewis, Natalie Uy, Lingzhi Hong +22 more

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

Communications Biology(2023)10.1038/s42003-023-04889-w

N/A

0.373DataRank · unranked

11 citations

Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, Ruping Shao +16 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0.373DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9024

N/A

0.360DataRank · unranked

10 citations

Mary W. Redman, Paul Wheatley‐Price, Bryan A. Faller, Liza C. Villaruz, Larry Corum +10 more

Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

eLife(2023)10.7554/elife.82618

Top 58%

0.271DataRank

Top 58%3 citations

Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M. Kuderer, David M. Aboulafia +92 more

Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

Clinical Lung Cancer(2024)10.1016/j.cllc.2024.04.003

N/A

0.208DataRank · unranked

3 citations

Cassandra Hennessy, Grace Wilson, Vidhyalakshmi Ramesh, Clara Hwang, Joy Awosika +27 more

Longitudinal Plasma Lipidomics Reveals Distinct Signatures Following Surgery in Patients with Glioblastoma

Metabolites(2025)10.3390/metabo15100673

N/A

0.104DataRank · unranked

1 citations

Yin Liu, Oliver Fiehn, Lina A. Dahabiyeh, Rubén Fragoso, Han Sung Lee +5 more

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9055

N/A

0.104DataRank · unranked

1 citations

Paul Frankel, Jonathan W. Riess, Anthony B. El-Khoueiry, Liza C. Villaruz, Stephen Leong +5 more

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.12.10.472153

N/A

0DataRank · unranked

1 citations

Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, Ruping Shao +14 more

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial

Nature Communications(2023)10.1038/s41467-023-40813-w

N/A

0DataRank · unranked

20 citations

Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina +18 more

Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2457

N/A

0DataRank · unranked

14 citations

Yvonne Wang, Gang Peng, Jianlei Gu, Mari Mino–Kenudson, Jonathan W. Riess +6 more

Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment

Biomedicines(2023)10.3390/biomedicines11082261

N/A

0DataRank · unranked

4 citations

Yin Liu, Lina A. Dahabiyeh, Ahmad Abuaisheh, Fangzhou Li, John Paul Aboubechara +6 more

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

The Medicine Forum(2023)10.1101/2023.03.09.23287038

Top 100%

0DataRank

Top 100%0 citations

Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M. Kuderer, David M. Aboulafia +92 more

Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox

npj Metabolic Health and Disease(2024)10.1038/s44324-024-00007-4

N/A

0DataRank · unranked

14 citations

Spencer R. Rosario, Jonathan W. Riess, Robert J. Canter, Sarbajit Mukherjee, Arta M. Monjazeb +2 more

Targeting MEK in non-small cell lung cancer

Current Problems in Cancer(2024)10.1016/j.currproblcancer.2024.101065

N/A

0DataRank · unranked

13 citations

Collin M. Blakely, Jonathan W. Riess, Matthew S. Lara

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100738

N/A

0DataRank · unranked

4 citations

Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan W. Riess, Tawee Tanvetyanon +8 more

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100706

N/A

0DataRank · unranked

2 citations

Matthew S. Lara, Miguel López de Rodas, Guillaume Luxardi, Samantha Herbert, Michiko Shimoda +9 more

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

Annals of Oncology(2025)10.1016/j.annonc.2025.09.140

N/A

0DataRank · unranked

8 citations

Y. Xia, Ke Pan, Fangdi Sun, Aaron C. Tan, Xinran Dong +31 more

Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT

European Journal of Nuclear Medicine and Molecular Imaging(2025)10.1007/s00259-025-07177-3

N/A

0DataRank · unranked

10 citations

Mohammad H. Madani, Fatma Şen, Hande Nalbant, Jonathan W. Riess, Yasser G. Abdelhafez +7 more

Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.03.004

N/A

0DataRank · unranked

4 citations

Rafael Parra‐Medina, Jonathan W. Riess, David R. Gandara, Luis G. Carvajal‐Carmona, Juan Pablo Castañeda-González

Plasma Lipidomics as a Novel Liquid Biopsy Approach for Glioblastoma

Preprints.org(2025)10.20944/preprints202506.0627.v1

N/A

0DataRank · unranked

0 citations

Yin Liu, Oliver Fiehn, Lina A. Dahabiyeh, Rubén Fragoso, Han Sung Lee +5 more

Older Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100873

N/A

0DataRank · unranked

0 citations

Lilit Vardanyan, Rebecca S. Boxer, Alex Fauer, Shiruyeh Schokrpur, D. Gandara +3 more

Supplementary Figure S3 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528346

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S5 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528337.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Data from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.c.6545696

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S2 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

INDIGO (University of Illinois at Chicago)(2023)10.1158/2159-8290.22528349.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Methods from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528328

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S2 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528349

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Data from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.c.6545696.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S4 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528343

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S5 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528337

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S3 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

INDIGO (University of Illinois at Chicago)(2023)10.1158/2159-8290.22528346.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Table S1 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528325

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S1 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

(2023)10.1158/2159-8290.22528352

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Table S1 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

Figshare(2023)10.1158/2159-8290.22528325.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S7 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

INDIGO (University of Illinois at Chicago)(2023)10.1158/2159-8290.22528331.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Methods from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

INDIGO (University of Illinois at Chicago)(2023)10.1158/2159-8290.22528328.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

Supplementary Figure S1 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

INDIGO (University of Illinois at Chicago)(2023)10.1158/2159-8290.22528352.v1

N/A

0DataRank · unranked

0 citations

Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton +15 more

A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS

Cancer Treatment and Research Communications(2020)10.1016/j.ctarc.2020.100174

N/A

0DataRank · unranked

14 citations

Nadine S. Jahchan, Millie Das, Michael Zach Koontz, Pamela L. Kunz, Heather A. Wakelee +4 more

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100151

N/A

0DataRank · unranked

4 citations

Rubii M. Tamen, Pablo Martínez, Alicia Sable-Hunt, Tony Addario, Pete Barbour +11 more

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.23.465573

N/A

0DataRank · unranked

18 citations

Celia Fernández-Méndez, Lauren Čech, Johnny Yu, Ismail M. Meraz, Victor Olivas +28 more

Jonathan W. Riess

Indexed papers

Top data-sharing exemplar

Papers